{"id":"erlotinib-temozolomide","safety":{"commonSideEffects":[{"rate":"40–80","effect":"Rash"},{"rate":"30–50","effect":"Diarrhea"},{"rate":"30–60","effect":"Nausea/vomiting"},{"rate":"20–40","effect":"Myelosuppression"},{"rate":"20–40","effect":"Fatigue"},{"rate":"10–20","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL810","moleculeType":"Small molecule","molecularWeight":"194.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erlotinib is a small-molecule tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling, preventing proliferation in EGFR-dependent cancers. Temozolomide is an alkylating agent that damages DNA and triggers apoptosis. The combination leverages dual mechanisms—targeted inhibition plus chemotherapy—to enhance anti-tumor activity, particularly in brain tumors and other malignancies.","oneSentence":"This combination uses erlotinib to inhibit EGFR signaling and temozolomide to alkylate DNA, together targeting cancer cell growth and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:24.479Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma or high-grade glioma (phase 3 trial)"},{"name":"EGFR-mutant or EGFR-overexpressing malignancies"}]},"trialDetails":[{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT01110876","phase":"PHASE1, PHASE2","title":"Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06","conditions":"Brain Cancer, Glioblastoma Multiforme","enrollment":21},{"nctId":"NCT02689336","phase":"PHASE2","title":"Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2016-08-06","conditions":"Glioma, Rhabdomyosarcoma, Osteosarcoma","enrollment":""},{"nctId":"NCT01182350","phase":"PHASE2","title":"Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)","status":"TERMINATED","sponsor":"Karen D. Wright MD","startDate":"2011-09","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":53},{"nctId":"NCT01284335","phase":"PHASE1","title":"A Safety Study in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2008-07","conditions":"Advanced Solid Tumors","enrollment":234},{"nctId":"NCT00720356","phase":"PHASE2","title":"Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2009-07-07","conditions":"Brain and Central Nervous System Tumors","enrollment":115},{"nctId":"NCT00096265","phase":"PHASE3","title":"Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-06","conditions":"Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7","enrollment":126},{"nctId":"NCT00187486","phase":"PHASE2","title":"Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-08","conditions":"Glioblastoma Multiforme, Gliosarcoma","enrollment":66},{"nctId":"NCT00086879","phase":"PHASE2","title":"Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2004-05","conditions":"Brain and Central Nervous System Tumors","enrollment":110},{"nctId":"NCT02015728","phase":"NA","title":"Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","status":"UNKNOWN","sponsor":"Seattle Children's Hospital","startDate":"2013-12","conditions":"Recurrent Childhood Brain Tumor","enrollment":20},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT00525525","phase":"PHASE2","title":"Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-09","conditions":"Glioblastoma, Gliosarcoma","enrollment":74},{"nctId":"NCT00385398","phase":"PHASE2","title":"QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC","status":"WITHDRAWN","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2008-07","conditions":"Lung Cancer, Metastatic Cancer","enrollment":""},{"nctId":"NCT00039494","phase":"PHASE2","title":"Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-12","conditions":"Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma","enrollment":171},{"nctId":"NCT00077454","phase":"PHASE1","title":"Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma","enrollment":95},{"nctId":"NCT00274833","phase":"PHASE2","title":"Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"David Peereboom","startDate":"2005-10","conditions":"CNS Tumor, Adult","enrollment":27},{"nctId":"NCT00268684","phase":"PHASE3","title":"Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":62,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Erlotinib, Temozolomide","genericName":"Erlotinib, Temozolomide","companyName":"Tel-Aviv Sourasky Medical Center","companyId":"tel-aviv-sourasky-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses erlotinib to inhibit EGFR signaling and temozolomide to alkylate DNA, together targeting cancer cell growth and survival. Used for Glioblastoma or high-grade glioma (phase 3 trial), EGFR-mutant or EGFR-overexpressing malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}